Drug Discovery Testing Compounds in Patient Samples by Automated Flow Cytometry

Area of Science:

• Oncology
• Biotechnology
• Pharmacology

Background:

• Developing reliable ex vivo assays to predict patient response to anticancer drugs is crucial for personalized cancer treatment.
• Existing functional assays often lack the ability to capture complex drug mechanisms or the patient's unique microenvironment.

Purpose of the Study:

• To introduce PharmaFlow, an automated flow cytometry platform for drug screening in hematological malignancies.
• To evaluate the platform's capability in predicting clinical response and identifying biomarkers using whole patient samples.

Main Methods:

• Development of an automated flow cytometry platform (PharmaFlow) for high-throughput drug screening.
• Utilizing peripheral blood or bone marrow samples from patients with hematological malignancies.
• Employing a robust data analysis system to capture multiple drug endpoints and mechanisms of action.

Main Results:

• PharmaFlow successfully evaluates multiple drug endpoints and complex mechanisms of action.
• The platform retains crucial microenvironmental components present in whole patient samples.
• Identified potential for predicting patient response to existing and novel treatments.

Conclusions:

• PharmaFlow offers a more clinically relevant and predictive ex vivo assay for personalized medicine in oncology.
• The platform can aid in preclinical drug discovery and biomarker identification for treatment sensitivity, resistance, and toxicity.
• This approach better recapitulates the human tumor microenvironment for improved drug response prediction.